Related references
Note: Only part of the references are listed.ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma
M. R. Yun et al.
ONCOGENE (2018)
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
Maria Bhatti et al.
Oncotarget (2018)
The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Yuan Yin et al.
CLINICAL CANCER RESEARCH (2017)
STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback
Ruolan Zeng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade
Alexandra Eichten et al.
CANCER RESEARCH (2016)
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong et al.
CANCER RESEARCH AND TREATMENT (2015)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition
Mahmoud Toulany et al.
CANCER BIOLOGY & THERAPY (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
The two faces of IL-6 in the tumor microenvironment
Daniel T. Fisher et al.
SEMINARS IN IMMUNOLOGY (2014)
Epidemiology: clues to the pathogenesis of Burkitt lymphoma
Ian Magrath
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Burkitt Lymphoma: Much More than MYC
David Dominguez-Sola et al.
CANCER CELL (2012)
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sandrine Sander et al.
CANCER CELL (2012)
Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+Breast Cancer by Expanding the Cancer Stem Cell Population
Hasan Korkaya et al.
MOLECULAR CELL (2012)
Aurora B kinase phosphorylates and instigates degradation of p53
Chris P. Gully et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas
Naoki Mori et al.
BIOCHEMICAL PHARMACOLOGY (2011)
IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells CRITICAL ROLE OF CYTOPLASMIC LOCALIZATION OF THE RNA-BINDING PROTEIN hnRNP A1
Yijiang Shi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells
Duo-Rong Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
L. S. Steelman et al.
LEUKEMIA (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion
Dimitrios Iliopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification
Elaine S. Jaffe et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
Juergen den Hollander et al.
BLOOD (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti-IL-6 Antibody
Angelique Gougelet et al.
PLOS ONE (2009)
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Patrizia Carpinelli et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells (Publication with Expression of Concern. See vol. 144, 2019)
Hua Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215
QY Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
H Katayama et al.
NATURE GENETICS (2004)
Share Paper
